NCT05067933 - A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 22, 2021

Primary Completion Date

June 10, 2022

Study Completion Date

May 9, 2023

Conditions

COVID-19

Interventions

DRUG

VXA-CoV2-1.1-S

COVID-19 (SARS-CoV-2) E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant Oral Tablet Vaccine

OTHER

Placebo Tablets

Placebo tablets matching the active vaccine tablets

Trial Locations (4)

AMR Knoxville, Knoxville

Velocity Clinical Research, Inc,, Cleveland

AMR Wichita East, Wichita

Ark Clinical Research, Long Beach